Anti-Complement C3a/C3a (desArg) Antibody, clone K13/16

Evaluated by Immunohistochemistry in human kidney tissue.

Immunohistochemistry Analysis: A 1:50 dilution of this antibody detected Complement C3a/C3a (desArg) in human kidney tissue sections.

Anti-Complement C3a/C3a (desArg), clone K13/16, Cat. No. MABF1978, is a mouse monoclonal antibody that detects Complement C3a and has been tested for use in Flow Cytometry, Immunohistochemistry (Paraffin), Neutralization, and Agonist and Inhibition studies.

Immunohistochemistry Analysis: A 1:50 dilution from a representative lot detected Complement C3a/C3a (desArg) in human liver and human tonsil tissue.

Agonist or Inhibitor Analysis: Administration of C3a induces a transient influx of Ca2+ release in a dose dependent manner (fluo-3 staining on human PMNs). In this regard, it functions as an agonist for the C3a receptor (Elsner, J., et. al. (1994). Blood. 83(11):3324-31).

Neutralizing Analysis: A representative lot detected Complement C3a/C3a (desArg) in Neutralizing applications (Elsner, J., et. al. (1994). Blood. 83(11):3324-31).

Flow Cytometry Analysis: A representative lot detected Complement C3a/C3a (desArg) in Flow Cytometry applications (Elsner, J., et. al. (1994). Blood. 83(11):3324-31).

Research Category
Inflammation & Immunology

Clone K13/16 recognizes complement C3a in human tissues. It targets an epitope that is present on human C3, C3a, and C3a-desArg.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

187.15 kDa calculated.

Complement C3 (UniProt: P01024; also known as C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1) is encoded by the C3 (also known as CPAMD1) gene (Gene ID: 718) in human. C3 is a secreted protein that plays a key role in the activation of the complement system. It s processing by C3 convertase is the central reaction in both classical and alternative complement pathways. C3 has an anaphylatoxon-like domain (aa 693-728) and a NTR (Netrin) domain (aa 1518-1661). IC3 precursor is first processed by the removal of four Arginine residues, forming two chains, beta and alpha, linked by a disulfide bond. C3 convertase activates C3 by cleaving the alpha chain, releasing C3a anaphylatoxin and generating C3b. C3a appears to be important in many inflammatory respons-es and the C3b fragment covalently binds to the cell or bacterial surface and plays a role in opsonisation. C3a anaphylatoxin is a mediator of local inflammatory process. In chronic inflammation, it acts as a chemoattractant for neutrophils. Defects in C3 gene can cause complement component 3 deficiency that leads to recurrent, severe, pyogenic infections because of ineffective opsonization of pathogens. Defects in C3 gene also cause age-related macular degeneration and hemolytic uremic syndrome that can lead to hemolytic anemia and renal failure

A full length native C3a fragment purified from human serum that was activated at 37°C for 1 hour by treatment with 10 mg/mL zymosan.

Concentration: Please refer to lot specific datasheet.

Format: Purified

Protein G purified

Purified mouse monoclonal antibody IgG1 in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Stable for 1 year at 2-8°C from date of receipt.